CH
ATXS

CVI Holdings’s Astria Therapeutics ATXS Stock Holding History

CVI Holdings’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,172
Closed -$584K – 44
2018
Q3 		$584K Sell
12,172
-32,507
-73% -$1.46M 0.97% 18
2018
Q2 		$2.57M Buy
+44,679
New +$4.12M 3.2% 8

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CVI Holdings's ATXS Position: Q4 2018 in Review

CVI Holdings sold out of Astria Therapeutics (ATXS) in Q4 2018, closing a stake of 12,172 shares — an estimated $584K sold.

CVI Holdings first reported a position in ATXS in Q2 2018 and held it in 2 quarters. The position peaked at $2.57M in Q2 2018. 23 funds tracked by Wall St. Rank hold ATXS as of Q4 2018.

  • CVI Holdings reported no remaining Astria Therapeutics position as of Q4 2018 after selling out during the quarter.
  • CVI Holdings sold 12,172 Astria Therapeutics shares in Q4 2018, an estimated $584K.
  • CVI Holdings first reported a position in Astria Therapeutics in Q2 2018 and held it in 2 quarters.
  • CVI Holdings's Astria Therapeutics position peaked at $2.57M in Q2 2018.
  • 23 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2018.

Based on CVI Holdings's 13F filing for Q4 2018, filed 14 Feb 2019.